ASX:OSL

Stock Analysis Report

Executive Summary

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for cancer in Australia.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • OncoSil Medical has significant price volatility in the past 3 months.
  • OncoSil Medical is covered by less than 3 analysts.

Share Price & News

How has OncoSil Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-11.8%

ASX:OSL

0.9%

AU Life Sciences

1.2%

AU Market


1 Year Return

-58.3%

ASX:OSL

-11.6%

AU Life Sciences

6.9%

AU Market

OSL underperformed the Life Sciences industry which returned -13.9% over the past year.

OSL underperformed the Market in Australia which returned 6.3% over the past year.


Share holder returns

OSLIndustryMarket
7 Day-11.8%0.9%1.2%
30 Day13.6%-0.4%4.9%
90 Day41.5%6.2%1.2%
1 Year-58.3%-58.3%-11.2%-11.6%13.1%6.9%
3 Year-37.5%-37.5%-39.0%-43.7%41.8%22.7%
5 Year-42.3%-42.3%-80.1%-86.6%48.2%15.7%

Price Volatility Vs. Market

How volatile is OncoSil Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OncoSil Medical undervalued based on future cash flows and its price relative to the stock market?

4.43x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for OncoSil Medical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for OncoSil Medical to establish if it is available at substantial discount.


Price Based on Earnings

OncoSil Medical is loss making, we can't compare its value to the Global Life Sciences industry average.

OncoSil Medical is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for OncoSil Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

OncoSil Medical is overvalued based on assets compared to the AU Life Sciences industry average.


Next Steps

Future Growth

How is OncoSil Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-13.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if OncoSil Medical is high growth as no revenue estimate data is available.

OncoSil Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare OncoSil Medical's revenue growth to the Australia market average as no estimate data is available.

Unable to compare OncoSil Medical's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.

Unable to compare OncoSil Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if OncoSil Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has OncoSil Medical performed over the past 5 years?

-14.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

OncoSil Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare OncoSil Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare OncoSil Medical's 1-year growth to the Global Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if OncoSil Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if OncoSil Medical has efficiently used its assets last year compared to the Global Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if OncoSil Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is OncoSil Medical's financial position?


Financial Position Analysis

OncoSil Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

OncoSil Medical has no long term commitments.


Debt to Equity History and Analysis

OncoSil Medical has no debt.

OncoSil Medical currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

OncoSil Medical has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

OncoSil Medical has less than a year of cash runway based on current free cash flow.

OncoSil Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.3% each year.


Next Steps

Dividend

What is OncoSil Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate OncoSil Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate OncoSil Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as OncoSil Medical has not reported any payouts.

Unable to verify if OncoSil Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as OncoSil Medical has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of OncoSil Medical's dividends in 3 years as they are not expected to pay a notable one for Australia.


Next Steps

Management

What is the CEO of OncoSil Medical's salary, the management and board of directors tenure and is there insider trading?

3.9yrs

Average management tenure


CEO

Daniel Kenny 0

4.7yrs

Tenure

AU$882,791

Compensation

Mr. Daniel Kenny has been the Chief Executive Officer of Oncosil Medical Limited since January 5, 2015 and serves as its Managing Director. Mr. Kenny served as Chief Commercial Officer and Vice President  ...


CEO Compensation Analysis

Daniel's remuneration is higher than average for companies of similar size in Australia.

Daniel's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.9yrs

Average Tenure

The tenure for the OncoSil Medical management team is about average.


Board Age and Tenure

2.6yrs

Average Tenure

The average tenure for the OncoSil Medical board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by OncoSil Medical individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyAU$9,98609 Sep 19
Martin Cross
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares135,000
Max PriceAU$0.074
BuyAU$32,78828 Aug 19
Christopher Roberts
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares500,000
Max PriceAU$0.066
BuyAU$1,36301 Jul 19
Merrill Lynch & Co. Inc., Banking Investments
EntityCompany
Shares26,724
Max PriceAU$0.051
BuyAU$837,12501 Jul 19
Merrill Lynch & Co. Inc., Banking Investments
EntityCompany
Shares17,373,584
Max PriceAU$0.048
BuyAU$2,418,35228 Jun 19
Regal Funds Management Pty Limited
EntityCompany
Shares30,234,447
Max PriceAU$0.08
SellAU$2,842,22628 Jun 19
Regal Funds Management Pty Limited
EntityCompany
Shares47,566,750
Max PriceAU$0.06
BuyAU$20,49609 May 19
Martin Cross
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares230,000
Max PriceAU$0.089
BuyAU$44,24702 May 19
Michael Bassett
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares800,000
Max PriceAU$0.055
BuyAU$19,25301 Apr 19
Martin Cross
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares358,333
Max PriceAU$0.054

Ownership Breakdown


Management Team

  • Charles Rowland (68yo)

    President of US Operations

    • Tenure: 0yrs
  • Michael Warrener

    Global Sales & Marketing Director

    • Tenure: 3.3yrs
  • Tom Milicevic (47yo)

    CFO & Company Secretary

    • Tenure: 3.9yrs
    • Compensation: AU$417.21k
  • David James

    Global Head of Manufacturing Operations

    • Tenure: 3.9yrs
  • Daniel Kenny

    CEO, MD & Executive Director

    • Tenure: 4.7yrs
    • Compensation: AU$882.79k
  • Ash Soman

    Chief Medical Officer

    • Tenure: 4.3yrs

Board Members

  • Chris Roberts (65yo)

    Non-Executive Chairman

    • Tenure: 2.3yrs
    • Compensation: AU$288.00k
  • Roger Aston (63yo)

    Non-Executive Director

    • Tenure: 6.5yrs
    • Compensation: AU$86.98k
  • Pierce Chow

    Member of Pancreatic Cancer Clinical Advisory Board

    • Tenure: 0yrs
  • Martin Cross

    Independent Non-Executive Director

    • Tenure: 2.6yrs
    • Compensation: AU$80.00k
  • Mike Bassett

    Non-Executive Director

    • Tenure: 0.8yrs
    • Compensation: AU$44.82k
  • Daniel Kenny

    CEO, MD & Executive Director

    • Tenure: 4.7yrs
    • Compensation: AU$882.79k
  • Joe Herman

    Member of Pancreatic Cancer Clinical Advisory Board

    • Tenure: 0yrs
  • Stephen Clarke

    Member of Pancreatic Cancer Clinical Advisory Board

    • Tenure: 0yrs
  • Richard Epstein

    Member of Pancreatic Cancer Clinical Advisory Board

    • Tenure: 0yrs
  • Dale Bailey

    Member of Pancreatic Cancer Clinical Advisory Board

    • Tenure: 0yrs

Company Information

OncoSil Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OncoSil Medical Limited
  • Ticker: OSL
  • Exchange: ASX
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$46.672m
  • Shares outstanding: 630.71m
  • Website: https://www.oncosil.com.au

Location

  • OncoSil Medical Limited
  • 50 Berry Street
  • Suite 402
  • North Sydney
  • New South Wales
  • 2060
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2005
N6ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2005
OSLCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2005

Biography

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for cancer in Australia. Its lead product is OncoSil, a brachytherapy device comprising OncoSil Phospho ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 10:37
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.